Inhibikase Therapeutics, Inc. Common Stock, Value, Issued
Inhibikase Therapeutics, Inc. (IKT) had Common Stock, Value, Issued of $132.03 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:CommonStockValue · last filed 2026-08-11
- 2026-06-30: Common Stock, Value, Issued $132.03K.
- 2026-03-31: Common Stock, Value, Issued $132.03K.
- 2025-12-31: Common Stock, Value, Issued $131.69K.
- 2025-09-30: Common Stock, Value, Issued $74.81K.
| Period end | Common Stock, Value, Issued | Common Stock, Value, Issued as first filed |
|---|---|---|
| 2026-06-30 | $132.03K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $132.03K 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $131.69K 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $74.81K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $74.52K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $74.34K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $69.36K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $7.46K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $7.22K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $6.48K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $6.19K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $5.36K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $5.29K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $31.06K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $4.22K 10-K · filed 2024-03-27 | $25.23K 10-K · filed 2023-03-31 |
| 2022-09-30 | $25.23K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $25.23K 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $25.23K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $25.16K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $25.16K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $25.13K 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $10.06K 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $10.05K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |